Form 8-K - Current report:
SEC Accession No. 0001558370-23-008300
Filing Date
2023-05-05
Accepted
2023-05-05 16:01:50
Documents
13
Period of Report
2023-05-02
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K fbio-20230502x8k.htm   iXBRL 8-K 33824
  Complete submission text file 0001558370-23-008300.txt   189073

Data Files

Seq Description Document Type Size
2 EX-101.SCH fbio-20230502.xsd EX-101.SCH 4438
3 EX-101.DEF fbio-20230502_def.xml EX-101.DEF 14627
4 EX-101.LAB fbio-20230502_lab.xml EX-101.LAB 16574
5 EX-101.PRE fbio-20230502_pre.xml EX-101.PRE 14299
7 EXTRACTED XBRL INSTANCE DOCUMENT fbio-20230502x8k_htm.xml XML 7166
Mailing Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154
Business Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154 781-652-4500
Fortress Biotech, Inc. (Filer) CIK: 0001429260 (see all company filings)

EIN.: 205157386 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35366 | Film No.: 23893656
SIC: 2834 Pharmaceutical Preparations